FDA Faces a Core Problem in Psychedelic Trials: Everyone Knows Who Got the Drug
A new opinion piece in The Clinical Trial Vanguard argues that psychedelic drug trials have a problem the FDA can no longer treat as secondary. In many studies, participants can tell when they received the active drug. So can therapists and raters. That makes these trials functionally open label, even when the protocol says they are blinded.
Looking for treatment? Find Spravato clinics (which is covered by insurance) and  ketamine clinics closest to you as well as other psychedelic therapies in your area.
| Key Issue | Why It Matters |
|---|---|
| Blinding often fails in psychedelic trials | Participants usually know when they received psilocybin, MDMA, LSD, or ayahuasca. |
| Expectancy may shape results | A patient who knows they received the active drug may report improvement partly because of that knowledge. |
| The FDA lacks a psychedelic specific framework | Current rules do not fully address drugs with unmistakable subjective effects. |
| MDMA offers a warning sign | The FDA rejected the MDMA assisted therapy application and asked for another Phase 3 trial. |
| Psilocybin may face the same question | Regulators may need to decide how much broken blinding they can accept. |
Why Blinding Matters
In a traditional randomized trial, blinding helps separate the drug effect from the expectation of treatment. That matters in depression, PTSD, and other psychiatric conditions, where self reported symptoms can shift with hope, attention, and therapeutic support.
Psychedelic trials make that separation much harder.
A person who receives a full dose of psilocybin may have hours of altered perception, emotion, and cognition. A person who receives a placebo, even an active placebo like niacin, usually has a very different experience. The difference is not subtle.
The article points to a review of 112 randomized psychedelic trials. In many of those studies, blinding failure was common. Some studies reported failure rates above 90 percent among participants or raters. Fewer than one third of the studies measured blinding integrity at all.
The Expectancy Problem
This does not mean psychedelic therapies do not work. It means the FDA has to decide how to read the evidence.
If a participant knows they received the active drug, their improvement may reflect several things at once. It may reflect the pharmacology of the compound. It may reflect the therapy and clinical setting. It may also reflect the emotional impact of knowing they received the treatment they hoped for.
That is especially important because psychedelic therapy is not usually delivered as a pill alone. It often includes preparation, a monitored dosing session, and integration afterward. The treatment model is already a drug plus context system.
For patients, that may be part of the appeal. For regulators, it creates a measurement problem.
MDMA Shows the Stakes
The issue is no longer theoretical. In 2024, the FDA rejected the application for MDMA assisted therapy for PTSD and asked for another Phase 3 trial. Functional unblinding was among the concerns around the evidence package.
That decision sent a clear signal to the field. Strong efficacy signals may not be enough if regulators cannot tell how much of the effect came from the drug itself.
Psilocybin programs could face a similar challenge. COMPASS Pathways received FDA Breakthrough Therapy designation for its COMP360 psilocybin therapy for treatment resistant depression in 2018. But Breakthrough status does not settle the blinding question. It only reflects early evidence of potential improvement over existing options.
What Happens Next
The FDA now faces a difficult choice. It could demand stronger blinding methods. It could require more rigorous reporting of blinding integrity. It could also decide that psychedelic treatments need a different approval framework because the drug experience is part of the therapeutic mechanism.
That last option may be the most honest. It would also be the hardest to regulate.
Psychedelic medicine is moving toward larger, more consequential trials. The central question is not only whether these treatments help patients. It is whether the field can prove that help in a way regulators can defend.
